24
Oct
2024

Intellia In Vivo Disappoints, Seaport Aims at Anxiety, & Wave Shows RNA Editing Promise

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Aliada’s Mega Return, GSK & AbbVie Eye T-Cell Engagers, and IPO Scorecard
Nobel for Protein Design and AlphaFold, Scholar Rock Shines, and a City is Born
BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK